---
figid: PMC1895551__zh80190601620001
figlink: /pmc/articles/PMC1895551/figure/fig1/
number: F1
caption: Prosurvival signaling pathways and their downstream targets. This is a schematic
  illustration of the principal pathways that are discussed in this paper. Growth
  factors induce, or membrane-associated molecules dimerize, spontaneously to activate
  mitogen-activated protein kinases (Raf/MEK/ERK) and PI3K/AKT signaling pathways.
  Transmembrane G protein–coupled receptors can activate PKC, which modulates the
  activity of Raf and MAPK pathway; both ERK1/2 and PKCα can serve as Bcl-2 kinases
  at serine 70. AKT and ERK induce phosphorylation of Bim (AKT, at serine 87 and ERK,
  at serines 55, 65, and 100), which attenuates the proapoptotic function of Bim,
  thereby promoting cell survival. Phosphorylation of Bad by MAPK (serine 112) or
  AKT (serine 136) inhibits apoptosis due to loss of the ability of Bad to heterodimerize
  with the survival proteins Bcl-2 and Bcl-XL. Hence, prosurvival phosphorylation
  of Bcl-2 family proteins modulates their antiapoptotic or proapoptotic activity
  at the mitochondrial membrane. This is complemented by AKT- or MAPK-driven gene
  transcription, which includes cyclins D and E (MAPK), cyclin-dependent kinase inhibitor
  p21, c-myc (AKT), which cause an increase in cell proliferation; and antiapoptotic
  proteins of the Bcl-2 (Mcl-1) and IAP (XIAP, survivin) families that regulate apoptosis
  at the level (Mcl-1) or downstream of mitochondria (IAPs). It is apparent that simultaneous
  activation of multiple signaling pathways might synergistically enhance prosurvival
  and proliferative potential of leukemic cells and the redundant downstream pathways
  negatively affect an ability of a particular signal transduction inhibitor to eliminate
  leukemia.
pmcid: PMC1895551
papertitle: Simultaneous activation of multiple signal transduction pathways confers
  poor prognosis in acute myelogenous leukemia.
reftext: Steven M. Kornblau, et al. Blood. 2006 Oct 1;108(7):2358-2365.
pmc_ranked_result_index: '166382'
pathway_score: 0.9090131
filename: zh80190601620001.jpg
figtitle: Prosurvival signaling pathways and their downstream targets
year: '2006'
organisms: Homo sapiens
ndex: d65ba656-df11-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC1895551__zh80190601620001.html
  '@type': Dataset
  description: Prosurvival signaling pathways and their downstream targets. This is
    a schematic illustration of the principal pathways that are discussed in this
    paper. Growth factors induce, or membrane-associated molecules dimerize, spontaneously
    to activate mitogen-activated protein kinases (Raf/MEK/ERK) and PI3K/AKT signaling
    pathways. Transmembrane G protein–coupled receptors can activate PKC, which modulates
    the activity of Raf and MAPK pathway; both ERK1/2 and PKCα can serve as Bcl-2
    kinases at serine 70. AKT and ERK induce phosphorylation of Bim (AKT, at serine
    87 and ERK, at serines 55, 65, and 100), which attenuates the proapoptotic function
    of Bim, thereby promoting cell survival. Phosphorylation of Bad by MAPK (serine
    112) or AKT (serine 136) inhibits apoptosis due to loss of the ability of Bad
    to heterodimerize with the survival proteins Bcl-2 and Bcl-XL. Hence, prosurvival
    phosphorylation of Bcl-2 family proteins modulates their antiapoptotic or proapoptotic
    activity at the mitochondrial membrane. This is complemented by AKT- or MAPK-driven
    gene transcription, which includes cyclins D and E (MAPK), cyclin-dependent kinase
    inhibitor p21, c-myc (AKT), which cause an increase in cell proliferation; and
    antiapoptotic proteins of the Bcl-2 (Mcl-1) and IAP (XIAP, survivin) families
    that regulate apoptosis at the level (Mcl-1) or downstream of mitochondria (IAPs).
    It is apparent that simultaneous activation of multiple signaling pathways might
    synergistically enhance prosurvival and proliferative potential of leukemic cells
    and the redundant downstream pathways negatively affect an ability of a particular
    signal transduction inhibitor to eliminate leukemia.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CASP3
  - MAPK3
  - SOS1
  - MAPK1
  - BCL2L11
  - PLCD4
  - PLCG2
  - PRKCE
  - BAD
  - SOS2
  - NRAS
  - PRKCB
  - PLCB2
  - BCL2
  - PLCB4
  - PLCD1
  - AKT1
  - PLCB3
  - AKT3
  - RAF1
  - PLCE1
  - AKT2
  - APAF1
  - KRAS
  - MAP2K1
  - MCL1
  - GRB2
  - PRKCD
  - PRKCA
  - PLCZ1
  - BRAF
  - PRKCI
  - PRKCG
  - PLCB1
  - ARAF
  - HRAS
  - PRKD3
  - PLCG1
  - PRKCH
  - MAP2K2
  - PRKCZ
  - PLCD3
  - PRKCQ
  - Tyrosine
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: Casp3
  symbol: CASP3
  source: hgnc_symbol
  hgnc_symbol: CASP3
  entrez: '836'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Bim
  symbol: BIM
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2L11
  entrez: '10018'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD4
  entrez: '84812'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG2
  entrez: '5336'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: Bad
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB2
  entrez: '5330'
- word: Bcl-2
  symbol: Bcl-2
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB4
  entrez: '5332'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD1
  entrez: '5333'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB3
  entrez: '5331'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCE1
  entrez: '51196'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Apaf-1
  symbol: APAF-1
  source: hgnc_alias_symbol
  hgnc_symbol: APAF1
  entrez: '317'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: Mcl-1
  symbol: Mcl-1
  source: hgnc_alias_symbol
  hgnc_symbol: MCL1
  entrez: '4170'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCZ1
  entrez: '89869'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCB1
  entrez: '23236'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCG1
  entrez: '5335'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: PLC
  symbol: PLC
  source: bioentities_symbol
  hgnc_symbol: PLCD3
  entrez: '113026'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
chemicals:
- word: Tyrosine
  source: MESH
  identifier: D014443
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC1895551__F1
redirect_from: /figures/PMC1895551__F1
figtype: Figure
---
